Showing 3291-3300 of 5685 results for "".
- Menarini Silicon Biosystems Begins Distribution of Rapid COVID-19 Antibody Test in North Americahttps://modernod.com/news/menarini-silicon-biosystems-begins-distribution-of-rapid-covid-19-antibody-test-in-north-america/2477887/
- Oxford Biomedica Snags Manufacturing Equipment to Ramp Up Production of COVID-19 Vaccinehttps://modernod.com/news/oxford-biomedica-snags-manufacturing-equipment-to-ramp-up-production-of-covid-19-vaccine/2477880/In the race for a COVID-19 vaccine, the University of Oxford has stormed to an early lead with the commercial manufacturing support of British drugmaker AstraZeneca. Now, in an effort to scale up capacity for global demand, one of AstraZeneca’s manufacturing partners has struck a deal for n
- American Medical Association’s New President a ‘Passionate Defender of the Independent Physician’https://modernod.com/news/american-medical-associations-new-president-a-passionate-defender-of-the-independent-physician/2477875/Susan Bailey, MD, the new president of the American Medical Association (AMA), called for physicians to advocate at the highest levels of government and insurance companies for support needed “to sustain private practice during a pandemic that threatens its very survival,” according t
- HHS Requiring Labs to Report Patients’ Race, Ethnicity With COVID-19 Tests in Effort to Combat Disparitieshttps://modernod.com/news/hhs-requiring-labs-to-report-patients-race-ethnicity-with-covid-19-tests-in-effort-to-combat-disparities/2477867/Following outcries from lawmakers and the public about the lack of demographic data for COVID-19 testing, the Trump administration is now requiring laboratories to collect demographic data like race, ethnicity, and sex when reporting test results, according to a FierceHealthcare
- SightGlass Vision Granted CE Mark for Eyeglasses That Slow Myopia Progression in Childrenhttps://modernod.com/news/sightglass-vision-granted-ce-mark-for-novel-eyeglasses-that-slow-myopia-progression-in-children/2477859/SightGlass Vision announced it has achieved CE Mark approval for its first product – novel eyeglasses designed to slow the progression of myopia in children. The approval allows the SightGlass Vision to commercialize its suite of Diffusion Optics Technology (DOT) products across the EU,
- CMS Increases Penalties Following Nearly 26K COVID-19 Nursing Home Deathshttps://modernod.com/news/cms-increases-penalties-following-nearly-26k-covid-19-nursing-home-deaths/2477852/The Trump administration has increased enforcement of states and nursing homes that have been repeat offenders for not following infection control practices, according to a FierceHealthcare
- Lilly Begins World’s First Human Study of Antibody to Treat COVID-19https://modernod.com/news/lilly-begins-worlds-first-human-study-of-antibody-to-treat-covid-19/2477853/Eli Lilly said that the first patients have been dosed in a phase 1 trial investigating the experimental antibody LY-CoV555 for the treatment of COVID-19. The company, which is developing the drug with partner AbCellera, noted that the move marks the world’s first study of a potential antib
- New Paper in Clinical and Experimental Optometry Summarizes SARS-CoV-2 Interaction With the Ocular Surfacehttps://modernod.com/news/new-paper-in-clinical-and-experimental-optometry-summarizes-sars-cov-2-interaction-with-the-ocular-surface/2477800/“The ocular surface, coronaviruses and COVID-19,” an extensive literature review now published in Clinical and Experimental Optometry, considers a number of questions regarding SARS-CoV-2 transmission and the ocular surface. In a complex and fast-moving subject area, the paper provides a
- Oculis Reports Topline Data From Phase 2 Trial With OCS-01 for Treating Inflammation and Pain Following Cataract Surgeryhttps://modernod.com/news/oculis-reports-topline-data-from-phase-2-trial-with-ocs-01-for-treating-inflammation-and-pain-following-cataract-surgery/2477782/Oculis SA reported positive results from its phase 2 SKYGGN study of OCS-01, a novel, high concentration, preservative free, topical SNP formulation of dexamethasone (ophthalmic suspension 1.5%) for the treatment of inflammation and pain following cataract surgery. OCS-01 has been develope
- ECPs Can Now Access Online Training to Certify to Prescribe CooperVision’s Brilliant Futures Myopia Management Programhttps://modernod.com/news/ecps-can-now-access-online-training-to-certify-to-prescribe-coopervisions-brilliant-futures-myopia-management-program/2477762/This month, CooperVision unveiled an online training curriculum so eye care professionals (ECPs) can certify to prescribe the Brilliant Futures Myopia Management Program featuring MiSight 1 day contact lenses. CooperVision will continue outreach to ECPs who have experience with pediatric populati